The cost-effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors in Sweden

Transfusion

Volumn 51, Issue 2, 2011, Pages 421-429

  Davidson, Thomas ^a   Ekermo, Bengt ^a   Gaines, Hans ^a   Lesko, Birgitta ^a   Åkerlind, Britt ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LIFESPAN; MALE; NEWBORN; NUCLEIC ACID ANALYSIS; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SEROLOGY; SWEDEN; VIRUS TRANSMISSION;

EID: 79951588653     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02877.x     Document Type: Article

References (39)

1. Shortt J, Polizzotto M, Waters N, Borosak M, Moran M, Comande M, Devine A, Jolley DJ, Wood EM,. Assessment of the urgency and deferability of transfusion to inform emergency blood planning and triage: the Bloodhound prospective audit of red blood cell. Transfusion 2009; 49: 2296-303.
2. Svensk förening för transfusionsmedicin. Transfusion services in Sweden 2008: extent, quality and safety. [cited 2010 Jun 20]., Ãrebro & Uppsala. 2009; 26-8.
3. Harritshoj L, Dickmeiss E, Hansen M, Ullum H, Jorgensen LB, Gerstoft J,. Transfusion-transmitted human immunodeficiency virus infection by a Danish blood donor with a very low viral load in the preseroconversion window phase. Transfusion 2008; 48: 2026-8.
4. Borkent-Raven BA, Janssen MP, van den Poel CL, de Wit GA, Bonsel GJ, van Hout BA,. Cost-effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands. Transfusion 2009; 49: 311-19.
5. Jackson BR, Busch MP, Stramer SL, AuBuchon JP,. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003; 43: 721-9. (Pubitemid 36629116)
6. Marshall DA, Kleinman SH, Wong JB, de Wit GA, Bonsel GJ, van Hout BA,. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang 2004; 86: 28-40. (Pubitemid 38200453)
7. Busch MP,. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? Transfus Clin Biol 2004; 11: 26-32. (Pubitemid 38230188)
8. Jarvis LM, Dow BC, Cleland A, Davidson F, Lycett C, Morris K, Webb B, Jordan A, Petrik J,. Detection of HCV and HIV-1 antibody negative infections in Scottish and Northern Ireland blood donations by nucleic acid amplification testing. Vox Sang 2005; 89: 128-34. (Pubitemid 41337050)
9. Van Hulst M, de Wolf JTM, Staginnus U, Ruitenberg EJ, Postma MJ,. Pharmaco-economics of blood transfusion safety: review of the available evidence. Vox Sang 2002; 83: 146-55. (Pubitemid 36807289)
10. Yeh JM, Botteman M, Pashos CL, Postma MJ, Staginnus U,. Economics of transfusion. Transfus Med Hemother 2002; 29: 218-25. (Pubitemid 34914048)
11. LäkemedelsförmÃ¥nsnämnden. General guidelines for economic evaluations from the Pharmaceutical Benefits Board: Stockholm. 2003.
12. Tynell E, Norda R, Montgomery M, Björkman A,. Diagnosis and procedure-specific survival among transfusion of recipients in 1993 and 2000, Ãrebro county, Sweden. Vox Sanguinis 2005; 88: 181-8. (Pubitemid 40516264)
13. Statistics Sweden. Livslängdstabell för 2009, uppdelat pÃ¥ män och kvinnor. [cited 2010 Jun 20]. Available from: URL:, 2009.
14. Coste J, Reesink HW, Engelfriet S, Laperche S,. International forum: implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to. Vox Sang 2003; 88: 289-303. (Pubitemid 40704905)
15. Biswas R, Tabor E, Hsia C,. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003; 43: 788-98. (Pubitemid 36629125)
16. Schreiber G, Busch MP, Kleinman SH, Koreliz J,. The risk of transfusion-transmitted viral infections. N Engl J Med 1996; 334: 1685-90. (Pubitemid 26193619)
17. von Sydow M, Gaines H, Sonnerborg A, Forsgren M, Pehrson PO, StrannegÃ¥rd Ã,. Antigen detection in primary HIV infection. BMJ 1988; 23: 238-40. (Pubitemid 18034707)
18. Lindback S, Thorstensson R, Karlsson A, von Sydow M, Flamholc L, Blaxhult A, Sönnerborg A, Biberfeld G, Gaines H,. Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study Group. AIDS 2000; 14: 2333-9.
19. Gaines H, von Sydow M, Sonnerborg A, Albert J, Czajkowski J, Pehrson PO, Chiodi F, Moberg L, Fenyö EM, Asjö B,. Antibody response in primary human immunodeficiency virus infection. Lancet 1987; 30: 1249-53. (Pubitemid 17070816)
20. Lindback S, Karlsson A, Mittler J, Blaxhult A, Carlsson M, Briheim G, Sönnerborg A, Gaines H,. Viral dynamics in primary HIV-1 infection. Karolinska Institue Primary HIV Infection Study Group. AIDS 2000; 14: 2283-91.
21. Harbarth S, Szucs T, Berger K, Jilg W,. The economic burden of hepatitis B in. Germany Eur J Epidemiology 2000; 16: 173-7.
22. El Saadany S, Coyle D, Giulivi A, Afzal M,. Economic burden of hepatitis C in Canada and the potential impact of prevention. Eur J Health Econom 2005; 6: 159-65. (Pubitemid 40905014)
23. Alert SBU,. Kombinationsbehandling vid kronisk hepatit C. Stockholm: SBU; 2000.
24. Roberts RR, Kampe LM, Hammerman M, Scott RD, Soto T, Ciavarella GG, Rydman RJ, Gorosh K, Weinstein RA,. The cost of care for patients with HIV from the provider economic perspective. AIDS Patient Care STDs 2006; 20: 876-86. (Pubitemid 46106074)
25. Ghatnekar O, Gisslén M, Hjortsberg C, Löthgren M,. Medical resource use and cost of HIV-related care in the HAART-era at a university clinic in Sweden. In 11th European AIDS conference. 2007. Madrid.
26. Niederau C, Fischer C, Kautz A,. Socio-economical aspects, quality of life and state of knowledge in hepatitis B patients. Socio-economical aspects in hepatitis B. Z Gastroenterol 2007; 45: 355-68.
27. Foberg U, Lindvall L, Richt B,. Transfusionssmittad-livssituation och vÃ¥rderfarenheter bland personer som smittats av hepatit C via blodtransfusion, in SHS. Linköping: Linköping University; 1995.
28. Eriksson R, Nordström G, Berglund T, Sandström E,. The health-related quality of life in a Swedish sample of HIV-infected persons. J Adv Nurs 2000; 32: 1213-23.
29. Burström K, Johannesson M, Diderichsen F,. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 2001; 10: 621-35. (Pubitemid 34056332)
30. Brooks R,. EuroQol: the current state of play. Health Policy 1996; 37: 53-72. (Pubitemid 26191458)
31. Dolan P,. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095-8.
32. Kamper-Jorgensen M, Hjalgrim H, Edgren G, Titlestad K, Ullum H, Shanwell A, Reilly M, Melbye M, Nyrén O, Rostgaard K,. Expensive blood safety initiatives may offer less benefit than we think. Transfusion 2010; 50: 240-2.
33. Custer B, Hoch J,. Cost-effectiveness analysis: what it really means for transfusion medicine decision making. Transfus Med Rev 2009; 23: 1-12.
34. Busch MP, Lee L, Satten G,. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion 1995; 35: 91-7.
35. Petersen L, Satten G, Dodd R,. Duration of time from HIV-1 infectiousness to development of detectable antibody. HIV seroconversion study group. Transfusion 1994; 283-9. (Pubitemid 24136182)
36. Roth WK, Weber M, Siifried E,. Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood bank setting. Lancet 1999; 353: 359-63. (Pubitemid 29088163)
37. Soldan K, Barbara J, Ramsay M, Hall A,. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immundeficiency virus infectious donations entering the blood supply in England, 1993-2001. Vox Sang 2003; 84: 274-86. (Pubitemid 36702334)
38. Weber B,. Screening of HIV infection: role of molecular and immunological assays. Expert Rev Mol Diagn 2006; 6: 399-411. (Pubitemid 44174344)
39. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH, NHLBI-REDS NAT Study Group. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005; 45: 254-64. (Pubitemid 40180144)